Switching to dolutegravir plus rilpivirine versus maintaining current antiretroviral therapy regimen in virologically suppressed people with HIV-1 and the Lys103Asn (K103N) mutation: 48-week results from a randomised, open-label pilot clinical trial
- Resource Type
- Article
- Source
- The Lancet HIV; March 2024, Vol. 11 Issue: 3 pe156-e166, 11p
- Subject
- Language
- ISSN
- 24054704; 23523018